Envista (NYSE:NVST) Given New $26.00 Price Target at JPMorgan Chase & Co.

Envista (NYSE:NVST) had its price objective raised by equities research analysts at JPMorgan Chase & Co. from $22.00 to $26.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential downside of 10.83% from the company’s previous close.

NVST has been the topic of a number of other research reports. Wells Fargo & Company upped their price target on Envista from $21.00 to $26.00 and gave the company an “equal weight” rating in a research report on Friday. Leerink Partners set a $35.00 price objective on Envista and gave the stock an “outperform” rating in a research note on Friday. Mizuho set a $24.00 target price on shares of Envista and gave the company a “neutral” rating in a research report on Tuesday, January 20th. William Blair upgraded shares of Envista from a “market perform” rating to an “outperform” rating in a research report on Friday. Finally, UBS Group boosted their price objective on Envista from $22.00 to $25.00 and gave the company a “neutral” rating in a research note on Tuesday. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $26.50.

Envista Trading Up 18.0%

Shares of Envista stock traded up $4.45 on Friday, hitting $29.16. The stock had a trading volume of 8,230,489 shares, compared to its average volume of 3,135,119. The stock has a 50 day moving average of $22.63 and a 200 day moving average of $21.16. The firm has a market capitalization of $4.79 billion, a P/E ratio of 324.00, a PEG ratio of 1.05 and a beta of 1.01. Envista has a twelve month low of $14.22 and a twelve month high of $29.13. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.02 and a current ratio of 2.37.

Envista (NYSE:NVST) last announced its quarterly earnings results on Thursday, February 5th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.06. The firm had revenue of $750.60 million during the quarter, compared to analysts’ expectations of $680.26 million. Envista had a net margin of 0.58% and a return on equity of 5.90%. The company’s revenue was up 15.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.24 EPS. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Sell-side analysts expect that Envista will post 1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Envista

Large investors have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC increased its holdings in Envista by 317.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,349 shares of the company’s stock worth $27,000 after purchasing an additional 1,026 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in Envista by 16,711.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock worth $31,000 after buying an additional 1,504 shares in the last quarter. Allworth Financial LP raised its position in Envista by 75.4% in the 4th quarter. Allworth Financial LP now owns 1,805 shares of the company’s stock valued at $39,000 after buying an additional 776 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Envista by 73.1% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock valued at $44,000 after acquiring an additional 949 shares in the last quarter. Finally, IFP Advisors Inc lifted its stake in Envista by 102.9% during the 4th quarter. IFP Advisors Inc now owns 2,112 shares of the company’s stock valued at $46,000 after acquiring an additional 1,071 shares in the last quarter.

Trending Headlines about Envista

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Q4 beat — Envista reported Q4 EPS and revenue ahead of Street estimates, with revenue up about 15% year-over-year, reflecting stronger demand. This is the primary catalyst for the stock rally. Read More.
• Positive Sentiment: Raised FY26 guidance — Management set FY2026 EPS guidance of $1.35–$1.45, above the consensus (~$1.27), signaling better-than-expected forward profitability and supporting optimism for 2026 earnings progression. Read More.
• Positive Sentiment: Market reaction and momentum — Multiple outlets note the stock “soared” after the print and guidance, and trading volume is elevated versus average, indicating broad investor buy interest on the beat/guidance combo. Read More.
• Neutral Sentiment: Analyst commentary & valuation context — Some outlets (Zacks) highlight Envista as a top-ranked value/growth candidate based on style scores and metrics; these analyses provide longer-term context but may not change near-term momentum. Read More.
• Neutral Sentiment: Investor materials available — The company posted its press release, slide deck and conference call; these will matter to investors digging into segment trends and margin drivers (neutral until specifics shift expectations). Read More.
• Negative Sentiment: Mixed analyst view on upside — Wells Fargo raised its price target from $21 to $26 but kept an “equal weight” rating; the PT is below the recent market price, indicating at least one major analyst sees limited near-term upside or some downside risk. Read More.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.